Table 2. Adverse events reported among chronic hepatitis C patients treated at a single centre in Germany.

Adverse events, n (%)	SOF/VEL overall (n = 115)	LDV/SOF overall (n = 249)
Patients with any AEs (Grades 3 & 4)	1 (0.9)	13 (5.2)
AEs 'probably' or 'possibly' related to treatment	2/2 (100)	10/13 (76.9)
AEs 'possibly' or 'possibly' related to SOF-treatment	2/2 (100)	3/13 (23.1)
AEs leading to discontinuation	2/2 (100)	0/13 (0.0)
AEs leading to hospitalization	0/2 (0.0)	0/13 (0.0)
Death	0/2 (0.0)	0/13 (0.0)

AEs: adverse events; LDV: ledipasvir; SOF: sofosbuvir; VEL: velpatasvir